Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2008 08:11 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals Completes $1 Million Financing

NEW YORK, Nov. 25, 2008 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that it has completed the first closing of a private placement of secured debt and warrants to...
July 31, 2008 16:05 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals Announces Results of Phase 2a Study of Topical PTH (1-34) for the Treatment of Psoriasis

NEW YORK, July 31, 2008 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced top-line results from its Phase 2a clinical study of topical PTH (1-34) for the treatment of...
June 13, 2008 08:08 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals Announces Amendment of Joint Venture Deal With Nordic Biotech

NEW YORK, June 13, 2008 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that the FDA has directed Hedrin(tm), a novel, non-insecticide treatment for pediculosis (head...
May 19, 2008 09:52 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals to Present At Rodman & Renshaw 5th Annual Global Healthcare Conference

NEW YORK, May 19, 2008 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that Douglas Abel, president and chief executive officer, will present at the Rodman &...
April 10, 2008 09:45 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals Announces Completion of Enrollment in Phase 2a Study of Topical PTH (1-34) for Psoriasis

NEW YORK, April 10, 2008 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced today that it has completed patient enrollment in its ongoing Phase 2a clinical study of Topical PTH...
March 26, 2008 09:45 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals to Trade on OTCBB Under New Ticker Symbol MHAN

NEW YORK, March 26, 2008 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that it has obtained a new ticker symbol, "MHAN". Effective immediately the company's common...
March 06, 2008 08:08 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals Successfully Completes Pre-IND Meetings for Altoderm and Altolyn

NEW YORK, March 6, 2008 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has concluded successful pre-IND (Investigational New Drug) meetings with the U.S. Food...
February 27, 2008 08:11 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals Announces Closing of Joint Venture With Nordic Biotech

NEW YORK, Feb. 27, 2008 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced the closing of its joint venture agreement with Nordic Biotech Venture Fund II K/S (Nordic) to...
February 22, 2008 16:17 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals to Voluntarily Withdraw Its American Stock Exchange Common Stock Listing

NEW YORK, Feb. 22, 2008 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has formally notified the American Stock Exchange ("AMEX") that it intends to voluntarily...
February 08, 2008 10:07 ET | Source: TG Therapeutics, Inc.

Manhattan Pharmaceuticals to Present At the BIO CEO & Investor Conference 2008

NEW YORK, Feb. 8, 2008 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the BIO CEO &...